Abstract
Tufts Center for the Study of Drug Development (CSDD) is a multidisciplinary research center at Tufts University School of Medicine. Tufts CSDD conducts research to explore the economic, regulatory, scientific, and political factors that affect the development and approval of new pharmaceutical products. In many of its studies, Tufts CSDD critically relies on broadly engaged team science to capture the views of and incorporate data provided by its varied stakeholders. These stakeholders include research-based pharmaceutical companies, contract service providers, clinical investigators, patient advocacy groups, technology companies, investors, government regulators, and the United States (US) Department of Defense. Their input is used to help design studies, create surveys, provide data, interpret results, and disseminate findings.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The Center for the Study of Drug Development was founded in 1976 at the University of Rochester in Rochester, NY, by visionary physician Dr. Louis Lasagna. The group moved to Tufts University in 1984.
References
Tufts Center for the Study of Drug Development. https://csdd.tufts.edu/
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
Cardiovascular drug approval rate in the U.S. fell as development time rose, according to the tufts center for the study of drug development (2017) Internet wire
Tufts CSDD Multi-Company Working Groups. https://csdd.tufts.edu/research-platforms-and-working-groups
Tufts CSDD Impact Reports. https://csdd.tufts.edu/impact-reports
Getz KA, Campo RA (2018) New benchmarks characterizing growth in protocol design complexity. Ther Innov Regul Sci 52(1):22–28. https://doi.org/10.1177/2168479017713039
Getz KA (2018) Transitions in the trial landscape: what will drive RCTs into the clinic? InVivo 36(5):16–22
Getz KA, Kaitin KI (2015) The impact of bad protocols. Chapter 10. In: Re-engineering clinical trials: best practices for streamlining the development process. Shüler P, Buckley B (eds). London: Elsevier, Academic Press
Kaitin K (ed) (2018) Rising protocol design complexity is driving rapid growth in clinical trial data volume. Tufts Center for the Study of Drug Development Impact Report, vol 20, no 4. Tufts University
Peña Y, Tse K, Hanrahan LM, de Bruin A, Morand EF, Getz K (2020) Establishing consensus understanding of the barriers to drug development in lupus. Ther Innov Regul Sci 54(5):1159–1165. https://doi.org/10.1007/s43441-020-00134-2
Manzi S, Raymond S, Tse K, Pena Y, Anderson A, Arntsen K, Bae SC, Bruce I, Dorner T, Getz K, Hanrahan L, Kao A, Morand E, Rovin B, Schanberg LE, Von Feldt JM, Werth VP, Costenbader K (2019) Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Sci Med 6(1):e000342. https://doi.org/10.1136/lupus-2019-000342
Tse K, Hanrahan L, Pena Y, Getz K (2019) ALPHA project unites global lupus community on barriers to research, drug development, care and access. Tufts Center for the Study of Drug Development White Paper
International Lupus Community Reaches First-Ever Agreement on Barriers to Research, Drug Development, Care and Access (2019). https://www.lupus.org/news/international-lupus-community-reaches-firstever-agreement-on-barriers-to-research-drug#. Accessed May 5, 2020
Lamberti MJ, Wilkinson M, Donzanti BA, Wohlhieter GE, Parikh S, Wilkins RG, Getz K (2019) A study on the application and use of artificial intelligence to support drug development. Clin Ther 41(8):1414–1426. https://doi.org/10.1016/j.clinthera.2019.05.018
Kaitin K (ed) (2019) Adoption of artificial intelligence is high across drug development. Tufts Center for the Study of Drug Development Impact Report, vol 21, no 3. Tufts University
Artificial Intelligence in Health Care: Benefits and challenges of machine learning in drug development (2020) https://www.gao.gov/products/GAO-20-215SP
Kaitin K (ed) (2014) New breakthrough therapy designation program aims to cut clinical trial time. Tufts Center for the Study of Drug Development Impact Report, vol 15, no 1. Tufts University
Xu L, Gao H, Kaitin KI, Shao L (2018) Reforming China’s drug regulatory system. Nat Rev Drug Discov 17(12):858–859. https://doi.org/10.1038/nrd.2018.150
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kaitin, K.I., Getz, K. (2022). Tufts Center for the Study of Drug Development Employs Broadly Engaged Team Science to Explore the Challenges of Pharmaceutical Research and Development. In: Lerner, D., Palm, M.E., Concannon, T.W. (eds) Broadly Engaged Team Science in Clinical and Translational Research. Springer, Cham. https://doi.org/10.1007/978-3-030-83028-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-83028-1_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-83027-4
Online ISBN: 978-3-030-83028-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)